Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study).
Elli EM, Iurlo A, Aroldi A, Caramella M, Malato S, Casartelli E, Maffioli M, Gardellini A, Carraro MC, D'Adda M, Polverelli N, Rossi M, Orofino N, Carrer A, Gambacorti-Passerini C, Antolini L, Passamonti F. Elli EM, et al. Among authors: antolini l. Br J Haematol. 2019 Sep;186(5):e123-e126. doi: 10.1111/bjh.15964. Epub 2019 May 20. Br J Haematol. 2019. PMID: 31106402 Free article. No abstract available.
3D-Informed Targeting of the Trop-2 Signal-Activation Site Drives Selective Cancer Vulnerability.
Guerra E, Trerotola M, Relli V, Lattanzio R, Tripaldi R, Ceci M, Boujnah K, Pantalone L, Sacchetti A, Havas KM, Simeone P, Travali N, Querzoli P, Pedriali M, Roversi P, Iezzi M, Tinari N, Antolini L, Alberti S. Guerra E, et al. Among authors: antolini l. Mol Cancer Ther. 2023 Jun 1;22(6):790-804. doi: 10.1158/1535-7163.MCT-22-0352. Mol Cancer Ther. 2023. PMID: 36921314
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis.
Cristoferi L, Porta M, Bernasconi DP, Leonardi F, Gerussi A, Mulinacci G, Palermo A, Gallo C, Scaravaglio M, Stucchi E, Maino C, Ippolito D, D'Amato D, Ferreira C, Nardi A, Banerjee R, Valsecchi MG, Antolini L, Corso R, Sironi S, Fagiuoli S, Invernizzi P, Carbone M. Cristoferi L, et al. Among authors: antolini l. Dig Liver Dis. 2023 Mar;55(3):373-380. doi: 10.1016/j.dld.2022.10.015. Epub 2022 Nov 7. Dig Liver Dis. 2023. PMID: 36357293 Free article.
Acute myeloid leukaemia niche regulates response to L-asparaginase.
Michelozzi IM, Granata V, De Ponti G, Alberti G, Tomasoni C, Antolini L, Gambacorti-Passerini C, Gentner B, Dazzi F, Biondi A, Coliva T, Rizzari C, Pievani A, Serafini M. Michelozzi IM, et al. Among authors: antolini l. Br J Haematol. 2019 Aug;186(3):420-430. doi: 10.1111/bjh.15920. Epub 2019 May 1. Br J Haematol. 2019. PMID: 31044436 Free article.
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation.
Diral E, Mori S, Antolini L, Abruzzese E, Le Coutre P, Martino B, Pungolino E, Elena C, Bergamaschi M, Assouline S, Di Bona E, Gozzini A, Andrade-Campos M, Stagno F, Iurlo A, Pirola A, Fontana D, Petiti J, Bonanomi ML, Crivori P, Piazza R, Fava C, Gambacorti-Passerini C. Diral E, et al. Among authors: antolini l. Blood. 2020 Nov 5;136(19):2237-2240. doi: 10.1182/blood.2019004371. Blood. 2020. PMID: 32518953 Free article. No abstract available.
Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study.
Gemelli M, Elli EM, Elena C, Iurlo A, Intermesoli T, Maffioli M, Pungolino E, Carraro MC, D'Adda M, Lunghi F, Anghileri M, Polverelli N, Rossi M, Bacciocchi M, Bono E, Bucelli C, Passamonti F, Antolini L, Gambacorti-Passerini C. Gemelli M, et al. Among authors: antolini l. Blood Res. 2020 Sep 30;55(3):139-145. doi: 10.5045/br.2020.2020130. Blood Res. 2020. PMID: 32792470 Free PMC article.
134 results